Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib plus Toripalimab in High-Risk Renal Cell Carcinoma
NCT05738694Phase 3Recruiting
- Start
- Apr 2023
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of axitinib and toripalimab in renal cell carcinoma (RCC) (2 arms). Primary endpoint: Disease-Free Survival at 2 years. Started Apr 2023; status: recruiting.
02
Drugs
axitinibtoripalimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05738694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738694.